Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience

Caleb J. Scheckel, Heidi E. Kosiorek, Richard Butterfield, Thai H Ho, Talal Hilal

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Germ cell tumors (GCTs) with malignant somatic transformation (MST) represent an uncommon variant of what is typically a curable malignancy. There is a paucity of data on time of somatic transformation, response to conventional therapy, and survival outcomes of different somatic subtypes. Methods: After obtaining institutional review board (IRB) approval, we searched our institutional database from 1982 to 2017 and identified patients with GCTs with MST. Patient characteristics, pathologic description, treatment, and clinical outcomes were extracted from the medical records. Results: We identified 24 cases of GCTs with MST; the MST was adenocarcinoma in 50% and sarcoma in 50%. Median age at diagnosis was 27. Alpha-fetoprotein and beta-human chorionic gonadotropin were undetectable in 44%, both were elevated in 54%. The majority were advanced stage (71% stage III), and International Germ Cell Cancer Collaborative Group (IGCCCG) risk was classified as 'good' in 60%. Median follow-up was 41 months (range 10-346 months). Median progression-free survival was 84 months (95% confidence interval (CI) 56-232), and median overall survival was 219 months (95% CI 165-not reported). Conclusion: Patients with GCTs with an MST appear to have poor responses to cisplatin-based chemotherapy, suggesting that somatic component-driven therapies should be considered. Furthermore, resection of residual disease when feasible is an essential component of management.

Original languageEnglish (US)
Pages (from-to)95-100
Number of pages6
JournalOncology Research and Treatment
Volume42
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Germ Cell and Embryonal Neoplasms
Confidence Intervals
Survival
Research Ethics Committees
alpha-Fetoproteins
Chorionic Gonadotropin
Sarcoma
Cisplatin
Disease-Free Survival
Medical Records
Adenocarcinoma
Databases
Drug Therapy
Therapeutics
Neoplasms

Keywords

  • Chemotherapy
  • Esophageal cancer
  • Metastatic
  • SCC
  • Squamous cell cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Germ Cell Tumors with Malignant Somatic Transformation : A Mayo Clinic Experience. / Scheckel, Caleb J.; Kosiorek, Heidi E.; Butterfield, Richard; Ho, Thai H; Hilal, Talal.

In: Oncology Research and Treatment, Vol. 42, No. 3, 01.03.2019, p. 95-100.

Research output: Contribution to journalArticle

Scheckel, Caleb J. ; Kosiorek, Heidi E. ; Butterfield, Richard ; Ho, Thai H ; Hilal, Talal. / Germ Cell Tumors with Malignant Somatic Transformation : A Mayo Clinic Experience. In: Oncology Research and Treatment. 2019 ; Vol. 42, No. 3. pp. 95-100.
@article{f40859f9f2004a86aade7085e43692c3,
title = "Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience",
abstract = "Background: Germ cell tumors (GCTs) with malignant somatic transformation (MST) represent an uncommon variant of what is typically a curable malignancy. There is a paucity of data on time of somatic transformation, response to conventional therapy, and survival outcomes of different somatic subtypes. Methods: After obtaining institutional review board (IRB) approval, we searched our institutional database from 1982 to 2017 and identified patients with GCTs with MST. Patient characteristics, pathologic description, treatment, and clinical outcomes were extracted from the medical records. Results: We identified 24 cases of GCTs with MST; the MST was adenocarcinoma in 50{\%} and sarcoma in 50{\%}. Median age at diagnosis was 27. Alpha-fetoprotein and beta-human chorionic gonadotropin were undetectable in 44{\%}, both were elevated in 54{\%}. The majority were advanced stage (71{\%} stage III), and International Germ Cell Cancer Collaborative Group (IGCCCG) risk was classified as 'good' in 60{\%}. Median follow-up was 41 months (range 10-346 months). Median progression-free survival was 84 months (95{\%} confidence interval (CI) 56-232), and median overall survival was 219 months (95{\%} CI 165-not reported). Conclusion: Patients with GCTs with an MST appear to have poor responses to cisplatin-based chemotherapy, suggesting that somatic component-driven therapies should be considered. Furthermore, resection of residual disease when feasible is an essential component of management.",
keywords = "Chemotherapy, Esophageal cancer, Metastatic, SCC, Squamous cell cancer",
author = "Scheckel, {Caleb J.} and Kosiorek, {Heidi E.} and Richard Butterfield and Ho, {Thai H} and Talal Hilal",
year = "2019",
month = "3",
day = "1",
doi = "10.1159/000495802",
language = "English (US)",
volume = "42",
pages = "95--100",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Germ Cell Tumors with Malignant Somatic Transformation

T2 - A Mayo Clinic Experience

AU - Scheckel, Caleb J.

AU - Kosiorek, Heidi E.

AU - Butterfield, Richard

AU - Ho, Thai H

AU - Hilal, Talal

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Germ cell tumors (GCTs) with malignant somatic transformation (MST) represent an uncommon variant of what is typically a curable malignancy. There is a paucity of data on time of somatic transformation, response to conventional therapy, and survival outcomes of different somatic subtypes. Methods: After obtaining institutional review board (IRB) approval, we searched our institutional database from 1982 to 2017 and identified patients with GCTs with MST. Patient characteristics, pathologic description, treatment, and clinical outcomes were extracted from the medical records. Results: We identified 24 cases of GCTs with MST; the MST was adenocarcinoma in 50% and sarcoma in 50%. Median age at diagnosis was 27. Alpha-fetoprotein and beta-human chorionic gonadotropin were undetectable in 44%, both were elevated in 54%. The majority were advanced stage (71% stage III), and International Germ Cell Cancer Collaborative Group (IGCCCG) risk was classified as 'good' in 60%. Median follow-up was 41 months (range 10-346 months). Median progression-free survival was 84 months (95% confidence interval (CI) 56-232), and median overall survival was 219 months (95% CI 165-not reported). Conclusion: Patients with GCTs with an MST appear to have poor responses to cisplatin-based chemotherapy, suggesting that somatic component-driven therapies should be considered. Furthermore, resection of residual disease when feasible is an essential component of management.

AB - Background: Germ cell tumors (GCTs) with malignant somatic transformation (MST) represent an uncommon variant of what is typically a curable malignancy. There is a paucity of data on time of somatic transformation, response to conventional therapy, and survival outcomes of different somatic subtypes. Methods: After obtaining institutional review board (IRB) approval, we searched our institutional database from 1982 to 2017 and identified patients with GCTs with MST. Patient characteristics, pathologic description, treatment, and clinical outcomes were extracted from the medical records. Results: We identified 24 cases of GCTs with MST; the MST was adenocarcinoma in 50% and sarcoma in 50%. Median age at diagnosis was 27. Alpha-fetoprotein and beta-human chorionic gonadotropin were undetectable in 44%, both were elevated in 54%. The majority were advanced stage (71% stage III), and International Germ Cell Cancer Collaborative Group (IGCCCG) risk was classified as 'good' in 60%. Median follow-up was 41 months (range 10-346 months). Median progression-free survival was 84 months (95% confidence interval (CI) 56-232), and median overall survival was 219 months (95% CI 165-not reported). Conclusion: Patients with GCTs with an MST appear to have poor responses to cisplatin-based chemotherapy, suggesting that somatic component-driven therapies should be considered. Furthermore, resection of residual disease when feasible is an essential component of management.

KW - Chemotherapy

KW - Esophageal cancer

KW - Metastatic

KW - SCC

KW - Squamous cell cancer

UR - http://www.scopus.com/inward/record.url?scp=85062401693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062401693&partnerID=8YFLogxK

U2 - 10.1159/000495802

DO - 10.1159/000495802

M3 - Article

C2 - 30820020

AN - SCOPUS:85062401693

VL - 42

SP - 95

EP - 100

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 3

ER -